Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 6/20 | 0.37 |
| ▸ | PPARG | P37231 | 5/20 | 0.37 |
| ▸ | CTSK | P43235 | 4/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13660687 | 1.00 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL10048032 | 1.00 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7871486 | 0.85 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL17995262 | 0.85 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL22398849 | 0.85 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL25272340 | 0.83 | CYP2D6 (0.41) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL13710929 | 0.83 | CYP2D6 (0.41) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL7268530 | 0.83 | CYP2D6 (0.41) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL13711119 | 0.83 | CYP2D6 (0.41) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL8486600 | 0.83 | CYP2D6 (0.41) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| CN-119350189-A | Method for preparing N-methyl-N-benzyloxycarbonyl-L-aspartic acid-4-tert-butyl ester | 上海农林职业技术学院 | 2025-01-24 | — | — | CN | disclosed |
| WO-2023127869-A1 | METHOD FOR PRODUCING N-ALKYL AMINO ACID AND PEPTIDE INCLUDING N-ALKYL AMINO ACID | 中外製薬株式会社 | 2023-07-06 | — | — | WO | disclosed |
| US-20230110994-A1 | CONJUGATES UNDERGOING INTRAMOLECULAR REARRANGEMENTS | ASCENDIS PHARMA A/S (DK) | 2023-04-13 | — | — | US | disclosed |
| US-20230056969-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-02-23 | — | — | US | disclosed |
| US-20230018413-A1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| EP-4084872-A1 | CONJUGATES UNDERGOING INTRAMOLECULAR REARRANGEMENTS | Ascendis Pharma A/S (DK) | 2022-11-09 | — | — | EP | disclosed |
| EP-4083051-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-11-02 | — | — | EP | disclosed |
| CN-115175738-A | Conjugates undergoing intramolecular rearrangement | 阿森迪斯药物股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20220305136-A1 | ANTI-CTLA4 CONJUGATES | ASCENDIS PHARMA GMBH (DE) | 2022-09-29 | — | — | US | disclosed |
| EP-3986479-A1 | ANTI-CTLA4 CONJUGATES | Ascendis Pharma Oncology Division A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-7960578-B2 | Method for the synthesis of peptides without solvent | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-06-14 | — | — | US | disclosed |
| US-20100016631-A1 | METHOD FOR THE SYNTHESIS OF PEPTIDES WITHOUT SOLVENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) (FR) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | CYP2D6 3388/4885HDAC3 2574/4885HDAC1 1887/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | CYP2D6 3388/4885HDAC3 2574/4885HDAC1 1887/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | CYP2D6 3388/4885HDAC3 2574/4885HDAC1 1887/4885 |
| US-20230056969-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | VIP, NGLY1, NPPA | CYP2D6 4754/4885HDAC3 4619/4885HDAC1 4598/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | CYP2D6 3388/4885HDAC3 2574/4885HDAC1 1887/4885 |
| US-20230110994-A1 | CONJUGATES UNDERGOING INTRAMOLECULAR REARRANGEMENTS | BCR, DHFR, ABL1 | CYP2D6 44/4885HDAC3 1088/4885HDAC1 3288/4885 |
| US-20100016631-A1 | METHOD FOR THE SYNTHESIS OF PEPTIDES WITHOUT SOLVENT | NRDC, NPPA, RTF1 | CYP2D6 1691/4885HDAC3 2729/4885HDAC1 3494/4885 |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | CYP2D6 4428/4885HDAC3 3736/4885HDAC1 3928/4885 |
| US-20230018413-A1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, OXTR | CYP2D6 2777/4885HDAC3 527/4885HDAC1 696/4885 |
| US-20220305136-A1 | ANTI-CTLA4 CONJUGATES | CD274, PDCD1LG2, PDCD1 | CYP2D6 3472/4885HDAC3 257/4885HDAC1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.